We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Largest COVID-19 Study of Hospitalized Patients in US Links Comorbidities to Acuity

By HospiMedica International staff writers
Posted on 30 Apr 2020
An analysis of the electronic health records (EHR) of hospitalized COVID-19 patients has uncovered several comorbidities as a key factor in the acuity of the disease.

The Northwell Health COVID-19 Research Consortium, with support from the Feinstein Institutes for Medical Research (Manhasset, NY, USA), described the clinical course and outcomes of 5,700 Northwell patients hospitalized with COVID-19 — the largest hospitalized patient cohort to date from the US — between March 1 and April 4.

The majority of patients in the study were male, and the median age of all patients being treated was 63 years old. More...
At triage, about of third of all patients (1,734) presented with a fever, 986 had a high respiratory rate and 1,584 patients received supplemental oxygen. On average, patients were discharged after four days. The mortality rates were higher for male patients than female at every adult 10-year age interval.

The Northwell Health Covid-19 Research Consortium’s findings demonstrated that hypertension (57%), obesity (41%) and diabetes (34%) were the most common comorbidities in the COVID-19 patients studied. Patients with diabetes were more likely to have received invasive mechanical ventilation, received treatment in the intensive care unit (ICU) or developed acute kidney disease.

Of the 2,634 hospitalized patients for whom outcomes were known, 14% were treated in the ICU, 12% received invasive mechanical ventilation and 3% were treated with kidney replacement therapy. As of April 4, 2020, for patients requiring mechanical ventilation (n = 1151, 20.2%), 38 (3.3%) were discharged alive, 282 (24.5%) died, and 831 (72.2%) remained in hospital.

“Through our consortium, we will share our clinical and scientific insights as we evolve the ways to care for and treat COVID-19 patients,” said Karina W. Davidson, PhD, MASc, professor and senior vice president at the Feinstein Institutes.

“These observational studies and other randomized clinical trial results from the Feinstein Institutes will improve the care for others confronting COVID outbreaks,” added Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes.

Related Links:
Feinstein Institutes for Medical Research


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.